Belite Bio posted positive top‑line results from its 104‑patient Phase III DRAGON trial: oral tinlarebant achieved the primary endpoint by slowing the growth rate of retinal lesions in Stargardt disease type 1 (STGD1). The company reported a 36% reduction in lesion growth versus placebo and signaled plans to submit regulatory filings, including in the U.S. Officials described tinlarebant as an oral modulator of retinol transport that reduces serum retinol‑binding protein 4 (RBP4), the mechanism Belite says underpins its clinical effect. The trial success positions the company to seek the first approved therapy for a rare inherited retinal disorder with no current treatments. Belite will now focus on regulatory strategy and filing timelines across jurisdictions while preparing for potential commercialization in a small, high‑unmet‑need patient population.